Lasa Supergenerics Ltd., a Mumbai-based veterinary active pharmaceutical intermediate maker, expects to maintain margin at 36-40 percent of gross profit level unless oil prices play further spoilsport.
In an interview to BloombergQuint, Omkar Herlekar, managing director at Lasa Supergenerics talked about the road ahead for the company. “We will be sticking to the veterinary space – feed and medicine – for our future growth plan.”
Watch the full conversation here:
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
